Glenmark Pharmaceuticals shares experienced a sharp 10% plunge earlier today, trading at ₹1,634.7. However, the stock has started to show signs of recovery as of 9:29 AM, trading 1.18% lower at ₹1,614.95 on the NSE.
Despite the dip, Glenmark Pharma has demonstrated significant growth over the past year, with its stock price surging from ₹785.7 to ₹1,634.7, marking a remarkable gain of 108.1%. This performance has outpaced the BSE Healthcare index, which rose from 28,646.0 to 43,479.0 over the same period, recording a 51.8% increase.
In the broader BSE Healthcare index, top losers today include Laurus Labs (down 2.6%) and Apollo Hospitals (down 1.9%). On the other hand, Procter & Gamble Health and FDC are among the top gainers, up 2.8% and 2.6%, respectively.
Among BSE Healthcare constituents, Glenmark Pharma stands out as one of the top performers over the past year, alongside Jubilant Pharmova (up 203.1%) and Suven Pharmaceuticals (up 116.7%), reflecting the robust growth in the pharma sector.
Investors are closely watching Glenmark’s movements today, as the stock attempts to stabilize after the sharp initial sell-off.
